Opendata, web and dolomites

iBILD

iBILD: Imaging Biomarker for Intelligent Lung Cancer Detection

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "iBILD" data sheet

The following table provides information about the project.

Coordinator
OPTELLUM LTD 

Organization address
address: OXFORD CENTRE FOR INNOVATION, NEW ROAD
city: OXFORD
postcode: OX1 1BY
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://www.optellum.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-04-01   to  2016-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    OPTELLUM LTD UK (OXFORD) coordinator 50˙000.00

Map

 Project objective

Lung cancer is one of the most common cancers with the highest mortality rate both in Europe and Worldwide. In 2012, 449,000 new cases were diagnosed with 388,000 deaths recorded in Europe alone. The reason for the 86% mortality rate is that most lung cancers are detected only after clinical symptoms are prevalent, by which time the cancer is in a late stage. Early detection using Chest Computed Tomography (CT) can lead to markedly improved outcomes, as shown recently by the NLST lung cancer screening trial in USA which has achieved a ground-breaking, 20% mortality reduction. However there is currently no solution that allows screening and management of suspected lung cancer patients in an economically sustainable manner. Optellum has developed a novel technology, Deep Learnt Biomarker (DLB). It is a software application that will allow radiologist to make a more accurate diagnosis by providing additional information extracted from the same CT, already acquired anyway as standard of care. It is based on machine learning algorithms applied to large databases of CTs with known ground-truth diagnosis, which learns patterns not obvious to a human eye. Our product will a) improve early diagnosis of lung cancer, b) save EUR799M p.a. in unnecessary costs to EU health providers c) enable European Union to become the leader in lung cancer screening.

Optellum was founded to commercialize machine learning technologies that will transform radiology by learning novel biomarkers from medical image databases. During this Phase 1 SME project, we will investigate the commercial feasibility of this first application and will develop a detailed business plan, with a focus on a roadmap to navigate the complex regulatory and health economics environment.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IBILD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IBILD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More